Recombinant Human Anti-CD20 Antibody (Ofatumumab)

Figure 1 Ofatumumab and rituximab exhibit modest direct antitumor activity against MCL cell lines.

MCL cell lines were utilized in alamarBlue reduction assays to investigate the direct antilymphoma activity of each antibody. Each antibody exhibited a time-dependent decrease in MCL cell viability following exposure to 10 μg/mL of each respective antibody in the presence of a cross-linking IgG antibody. With the exception of the Mino cell line at the 72-hour time point, all cell lines demonstrated similar degrees of direct antitumor activity with ofatumumab and rituximab at the dose tested (*, P < 0.05).

Barth, M. J., Mavis, C., Czuczman, M. S., & Hernandez-Ilizaliturri, F. J. (2015). Ofatumumab exhibits enhanced in vitro and in vivo activity compared to rituximab in preclinical models of mantle cell lymphoma. Clinical Cancer Research, 21(19), 4391-4397.

Figure 2 Ofatumumab induces significantly higher levels of CDC-associated cell lysis than rituximab.

MCL tumor cell lines were tested for CDC cell lysis using a 51Cr release assay with human serum from normal healthy donors as a source of complement. In all MCL cell lines tested, with the exception of Granta, ofatumumab was more effective than rituximab at inducing CDC lysis at a dose of 10 μg/mL. (*, P < 0.05).

Barth, M. J., Mavis, C., Czuczman, M. S., & Hernandez-Ilizaliturri, F. J. (2015). Ofatumumab exhibits enhanced in vitro and in vivo activity compared to rituximab in preclinical models of mantle cell lymphoma. Clinical Cancer Research, 21(19), 4391-4397.